Background: A healthy sleep-wake cycle is fundamental for regulating immune function. Sleepiness and fatigue are often manifestations of chronic inflammatory disorders, such as inflammatory bowel disease (IBD), potentially influencing the course of the disease. Our aim was to characterize sleep impairment in patients with IBD and to identify potential associated factors.
Methods: We conducted a single-center prospective case control study including IBD patients and healthy controls. We evaluated clinical and biochemical parameters, sleep impairment through Pittsburgh Sleep Quality Index (PSQI) and anxiety and depression through Hospital Anxiety and Depression Scale (HADS) questionnaires.
Results: In total, 110 patients with IBD and 66 healthy controls were included. Patients with IBD had a significantly altered sleep quality compared to the control group ( < 0.001), with sleep impairment also occurring for patients in remission (median PSQI = 7), but without significant differences between ulcerative colitis and Crohn's disease. However, PSQI was correlated with disease activity scores only for ulcerative colitis and not for Crohn's disease. Among patients with increased PSQI, only 30.19% used sleep medication. Sleep impairment was significantly correlated with altered psychological status ( < 0.01) and the presence of extraintestinal manifestations ( = 0.0172).
Conclusions: Sleep impairment is frequent among patients with IBD, is associated with psychological distress and several disease-related parameters and should be routinely evaluated, at least in several IBD patient subgroups, to improve disease management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408531 | PMC |
http://dx.doi.org/10.3390/jcm9072304 | DOI Listing |
Sleep
January 2025
Department of Psychology, Faculty of Science, Memorial University, St. John's, NL, Canada.
Study Objectives: Cancer-related fatigue is one of the most common symptoms in cancer survivors. Cognitive behavioural therapy for insomnia (CBT-I) can improve fatigue, but mechanisms are unclear. This secondary analysis of a randomized controlled trial evaluated whether CBT-I led to a significant improvement in fatigue, accounting for change in comorbid symptoms of insomnia, perceived cognitive impairment (PCI), anxiety, and depression.
View Article and Find Full Text PDFArch Dermatol Res
January 2025
Blood Purification Center, Zhejiang Hospital, 1229 Gudun Road, Xihu District, Hangzhou, Zhejiang, 310030, China.
Uremic pruritus (UP) is a debilitating condition frequently associated with chronic kidney disease, severely impairing patients' quality of life and contributing to increased mortality. Recent studies have suggested that intravenous sodium thiosulfate (STS) may offer therapeutic relief for pruritus in patients undergoing hemodialysis. To assess its effectiveness, we conducted a systematic review and meta-analysis to explore the potential of intravenous STS in managing UP.
View Article and Find Full Text PDFSpinal Cord
January 2025
Rehabilitation Studies, Faculty of Medicine and Health, The University of Sydney, The Kolling Institute, Northern Sydney Local Health District, St Leonards, NSW, Australia.
Study Design: Narrative review OBJECTIVES: Sir Ludwig Guttmann realised spinal cord injury (SCI) rehabilitation should incorporate more than a biomedical approach if SCI patients were to adjust to their injury and achieve productive social re-integration. He introduced components into rehabilitation he believed would assist his patients build physical strength as well as psychological resilience that would help them re-engage with their communities. We pay tribute to Sir Ludwig by presenting research that has focussed on psychosocial factors that contribute to adjustment dynamics after SCI.
View Article and Find Full Text PDFPrim Care Companion CNS Disord
January 2025
Eisai Inc, Nutley, New Jersey.
Insomnia and some insomnia treatments can impact an individual's daytime functioning. Here, we performed post hoc analyses of patient-reported outcomes from a phase 3 clinical trial to assess the impact of lemborexant (LEM), a dual orexin receptor antagonist, on daytime functioning. Adults with insomnia were randomized 1:1:1 to receive placebo, LEM 5 mg (LEM5) or LEM 10 mg (LEM10) for 6 months.
View Article and Find Full Text PDFPLoS One
January 2025
School of Human Nutrition, McGill University, Montreal, Québec, Canada.
Objective: Managing blood glucose levels is challenging for elite athletes with type 1 diabetes (T1D) as competition can cause unpredictable fluctuations. While fear of hypoglycemia during physical activity is well documented, research on hyperglycemia-related anxiety (HRA) is limited. HRA refers to the heightened fear that hyperglycemia-related symptoms will impair functioning.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!